Euroapi Company Header Euroapi Company Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of UCLA Jonsson Comprehensive Cancer Center.

    Client Virtual Booth

    UCLA JONSSON COMPREHENSIVE CANCER CENTER

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    UCLA Jonsson Comprehensive Cancer Center
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    200 Ucla Medical Plaza, Los Angeles, CA 90095
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://cancer.ucla.edu/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/jonsson-cancer-center/
    Twitter
    Twitter
    https://twitter.com/uclajccc

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Potential COVID-19 Treatment Identified in UCLA-Led Lab Study

    Details:

    Berzosertib, which is licensed by Merck KGaA, Darmstadt, Germany, is being investigated in separate early- and mid-stage clinical trials in combination with chemotherapy as a possible treatment for small-cell lung cancer, ovarian cancer and other types of tumors.


    Lead Product(s): Berzosertib

    Therapeutic Area: Infections and Infectious Diseases Product Name: M6620

    Highest Development Status: UndisclosedProduct Type: Small molecule

    Recipient: Merck Group

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 24, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Drug Combination “Breakthrough” Gives Longest-Ever Survival in Patients with Nonresectable Liver Cancer

    Details:

    Atezolizumab is an immune checkpoint inhibitor drug, which helps the immune system hunt down and destroy cancer.


    Lead Product(s): Atezolizumab,Bevacizumab

    Therapeutic Area: Oncology Product Name: Tecentriq

    Highest Development Status: ApprovedProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable February 06, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    famar-2024-07-22

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search